LEBRIKIZUMAB IMPROVES ATOPIC DERMATITIS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB: RESULTS FROM THE ADAPT STUDY
Recommended Citation
Taudorf EH, Silverberg J, Ackerman L, Bagel J, Stein Gold LF, Blauvelt A, Rosmarin D, Chovatiya R, Zirwas M, Yosipovitch G, Waibel J, Murase J, Lockshin B, Weisman J, Simpson E. LEBRIKIZUMAB IMPROVES ATOPIC DERMATITIS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB: RESULTS FROM THE ADAPT STUDY. Acta Derm Venereol 2025; 105:37.
Document Type
Conference Proceeding
Publication Date
5-6-2025
Publication Title
Acta Derm Venereol
Abstract
Purpose: To evaluate the efficacy and safety of lebrikizumab (LEB) in patients with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab (DUPI) (ADapt, NCT05369403).Methods: ADapt is an open-label, Phase 3b, 24-week(W) study. Patients must have discontinued DUPI due to inadequate response (non-response, partial response, or loss of response), intolerance or an adverse event (AE), or other reasons. ≥ 4W after discontinuing DUPI, patients received a 500-mg LEB loading dose at Baseline and at W2 followed by 250mg every 2W through W16 (Q2W). At W16, responders (IGA 0/1 with ≥ 2-point improvement (IGA0/1) or EASI75 [primary endpoint]) received LEB 250mg Q4W; other patients continued with 250mg Q2W. Q2W and Q4W pooled-data were analyzed as-observed and non-responder/multiple imputa-tion (NRI/MI). Results: 86 patients were enrolled (56% discontinued DUPI due to inadequate-response, 16% due to intolerance/AEs to DUPI, and 28% other reasons). For all patients, the proportion of patients (W16 and W24) achieving: 1) EASI75: 57.4% and 60.0%, as-ob-served; 50.7% and 52.8% NRI/MI; 2) IGA0/1: 38.7% and 38.2%, as-observed; 35.6% and 36.8%, NRI/MI; 3) Face-IGA 0: 42% and 49%, as-observed; 4) Pruritus NRS ≥ 4-point improvement 53.2% and 61.5% as-observed; 48.8% and 47.9% NRI/MI; and 5) DLQI ≥ 4-point improvement 83.0% and 83.0% as-observed. The safety profile was consistent with other LEB Phase 3 trials. Four patients who discontinued DUPI due to conjunctivitis did not report conjunctivitis with LEB. 3.5% of patients reported treatment-emergent conjunctivitis. Conclusions: In DUPI-experienced patients, treatment of mode-rate-to-severe AD with LEB resulted in meaningful improvements in skin clearance, itch, and quality of life.
Volume
105
First Page
37
